deltatrials
Active Not Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT03913143

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) (ILLUMINATE)

Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Sponsor: ProQR Therapeutics

Conditions Blindness Eye Diseases Eye Diseases, Hereditary Eye Disorders Congenital Leber Congenital Amaurosis Leber Congenital Amaurosis 10 Neurologic Manifestations Retinal Disease Sensation Disorders Vision Disorders
Interventions Sham sepofarsen
Updated 16 times since 2019 Last updated: Mar 2, 2022 Started: Apr 4, 2019 Primary completion: Jan 31, 2022 Completion: Mar 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Blindness and Eye Diseases and is currently ongoing. ProQR Therapeutics leads this study, which shows 16 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2022 · 14 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Feb 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

▶ Show 11 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2_PHASE3

  2. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  3. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2_PHASE3

  4. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE2_PHASE3

  5. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2_PHASE3

  6. Apr 2020 — Jul 2020 [monthly]

    Recruiting PHASE2_PHASE3

  7. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2_PHASE3

  8. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2_PHASE3

  9. Oct 2019 — Feb 2020 [monthly]

    Recruiting PHASE2_PHASE3

  10. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2_PHASE3

  11. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ProQR Therapeutics
Data source: ProQR Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Belo Horizonte, Brazil , Ghent, Belgium , Giessen, Germany , Iowa City, United States , London, United Kingdom , Montreal, Canada , Naples, Italy , Paris, France , Rotterdam, Netherlands and 4 more locations